The FDA has taken a significant procedural step toward a potential shift in federal peptide compounding policy. On October 14, 2026, the Office of Information and Regulatory Affairs (OIRA), housed within the White House’s Office of Management and Budget (OMB), received an FDA submission formally titled “Interim Access Policy for Compounding Using Certain Peptides.” The document is currently listed as pending review.
The submission addresses enforcement discretion for compounding certain peptides — a framework that could determine whether compounders may legally produce substances such as BPC-157, TB-500, KPV, MOTS-c, emideltide, semax, and epitalon-related bulk drug substances without facing immediate FDA enforcement action. The policy text itself has not been made public.
This is a procedural milestone, not a final regulatory decision. No enforcement posture has changed yet. However, the formal title and substance of the OMB submission confirm that the FDA is actively moving forward with an interim approach to peptide compounding.
What happened
The October 14 OIRA submission follows the July 23–24, 2026 meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC). That meeting addressed several bulk drug substances used in peptide compounding, including BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon-related substances.
The interim access policy now sits with OIRA for review. OIRA typically evaluates regulatory actions for cost, legal consistency, and policy implications before a federal agency finalizes and publishes them. The review process does not guarantee a specific outcome or timeline.
Why it matters
For 503A and 503B compounding pharmacies, the interim policy could establish the terms under which certain peptides may be compounded under enforcement discretion — meaning the FDA may choose not to take immediate action against compounders for specific substances, even if those substances have not gone through formal drug approval.
For telehealth companies that partner with compounding pharmacies, the policy could clarify which peptides their compounding partners may offer. For consumers, access to compounded peptides could shift depending on the final terms of the policy once published.
The stakes are significant because the peptides under discussion — particularly BPC-157 and TB-500 — remain widely used in compounded and consumer markets despite lacking FDA-approved drug products. The interim policy represents the official regulatory pathway that will shape how these substances can be legally compounded going forward.
What to watch next
- OIRA review completion: Watch for the policy to clear OIRA review and move toward publication, which would reveal the specific enforcement discretion terms.
- Final policy text: The actual language of the interim access policy has not been released. The details will determine which peptides are covered and under what conditions.
- Stakeholder responses: Compounding pharmacies, telehealth companies, and consumer advocacy groups are likely to respond once the policy terms become public.
- Related advocacy activity: A separate citizen petition from the Partnership for Safe Medicines urging the FDA to block bulk compounding of unapproved peptides remains part of the broader regulatory landscape.
Sources
- Legal 500 — FDA Submits Interim Peptide Compounding Policy for White House Review
- POLITICO Prescription Pulse — Peptide Plan Heads to White House for Review
Industry information only. Not medical or legal advice.
